Drugs / AUR106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05861947 | Aug 2023 → Feb 2026 | colorectal cancer, esophageal cancer, gastric cancer, kidney cancer +2 | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05861947 ↗ |
| Route | Oral | “The safety and tolerability of oral AUR106 will be evaluated” NCT05861947 ↗ |